Trubion Hires Stromatt as Chief Medical Officer, Replacing Burge

Luke Timmerman8/18/08

Trubion Pharmaceuticals, the Seattle-based developer of treatments for autoimmune diseases, said today it has hired Scott Stromatt as senior vice president and chief medical officer. Stromatt previously oversaw clinical and regulatory affairs at Seattle-based Cell Therapeutics until he resigned in April. He will replace Daniel Burge, who is leaving the company in late August for “personal reasons,” the company said. Burge, 46, a veteran of Amgen and Immunex, joined Trubion in 2004.

Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.